CompletedNCT01510873
Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP)
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Principal Investigator
- Fabio Efficace, PhDGIMEMA DATA CENTER, ROME, ITALY
- Intervention
- HRQOL evaluation(other)
- Enrollment
- 424 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2014
Study locations (29)
- Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
- Ospedale Generale Regionale "F. Miulli", Acquaviva delle Fonti, Italy
- Azienda Ospedaliero-Universitaria Policlinico Consorziale, Bari, Italy
- Azienda Sanitaria Locale BA - Ospedale di Venere, Bari, Italy
- Ospedali Riuniti di Bergamo, Bergamo, Italy
- Ospedale Binaghi, Cagliari, Italy
- Ospedale Businco, Cagliari, Italy
- U.O.C. di Onco-Ematologia - Centro di Ricerca e Formazione ad Alta tecnologia nelle Scienze Biomediche, Campobasso, Italy
- US Dipartimentale - Centro per le malattie del sangue - Ospedale Civile - S.Giacomo, Castelfranco Veneto, Italy
- Azienda Ospedaliero Universitaria, Foggia, Italy
- Azienda Ospedaliera Universitaria San Martino, Genova, Italy
- DIMI- Clinica Ematologica - Università degli studi di Genova, Genova, Italy
- Ospedale Santa Maria Goretti, Latina, Italy
- Azienda Ospedaliera Ospedali Riuniti "Papardo Piemonte", Messina, Italy
- Azienda Ospedaliera Universitaria - Policlinico "G. Martino", Messina, Italy
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01510873 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation